Analyst Confidence Surges for Assembly Biosciences Pipeline
Published on 09/25/2025 at 12:54 | Redaktion boerse-global.de
A wave of positive analyst sentiment is bolstering the outlook for Assembly Biosciences, with Citizens JMP initiating coverage on the biotech stock. The firm issued a “Market Outperform” rating and set a price target of $38, arguing that the market is significantly underestimating the company’s developmental pipeline. According to analyst Roy Buchanan, the oral antiviral drug candidates possess substantial potential, making a notable upward price correction a likely scenario.
The foundation for this optimism is rooted in concrete clinical progress. Assembly Biosciences has reported promising interim results from a Phase 1b study for ABI-5366, which targets recurrent genital herpes. Furthermore, encouraging outcomes have emerged from a separate Phase 1b trial evaluating ABI-4334 for the treatment of chronic hepatitis B virus. These... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
